Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Date:10/21/2008

3 N/A N/A

WORLDWIDE $1,978 $2,048 (3%) (6%)

Growth rates are based on actual, non-rounded amounts.

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Change

As

Nine Months Ended Reported Constant

September 30, Currency Currency

In millions 2008 2007 Basis Basis

DOMESTIC $3,330 $3,397 (2%) (2%)

EMEA 1,509 1,352 12% 1%

INTER-CONTINENTAL 1,147 1,048 9% (1%)

INTERNATIONAL 2,656 2,400 11% 0%

DIVESTED BUSINESSES 62 407 N/A N/A

WORLDWIDE $6,048 $6,204 (3%) (7%)

Change

As

Nine Months Ended Reported Constant

September 30, Currency Currency

In millions 2008 2007 Basis Basis

INTERVENTIONAL CARDIOLOGY $2,158 $2,257 (4%) (9%)

PERIPHERAL INTERVENTION 452 445 1% (3%)

CARDIOVASCULAR 2,610 2,702 (3%) (8%)

NEUROVASCULAR 272 260 4% (3%)

PERIPHERAL EMBOLIZATION 68 71 (3%) (6%)

NEUROVASCULAR 340
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
2. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
3. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
4. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
5. Boston Scientific to Participate in UBS Global Life Sciences Conference
6. Boston Scientific Announces Court Decision
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
9. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
10. TechCFO Adds Gary Strickland as Partner in Boston Office
11. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 RURO ... ezColony version 4.1, a versatile refinement to the ... software solution, improves its advanced methodical management for ... with ezColony 4.1. The network-based platform provides user ... effective research. While continuing to emphasize streamlined tasks, ...
(Date:5/17/2013)... Darrington, WA (PRWEB) May 17, 2013 Tooth ... 5th graders showing active signs of the disease. The World ... children and nearly 100% of adults have cavities. What are ... Research is showing a strong connection between the oral ... why is this disease so rampant, yet it is also ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... CEL-SCI Corporation (NYSE AMEX: CVM ... treatment for the "swine flu and related H1N1" flu ... System) vaccine technology. The Company plans to utilize ... protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a ...
... and AMSTERDAM, May 26 ,Agendia, a world leader ... its U.S. clinical genomics laboratory in Huntington Beach, ... Clinical Laboratory,Improvements Amendments (CLIA) as administered by the ... In addition to opening its ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: ... and supplier,of branded generic and innovative pharmaceuticals ... a 37.5% stake in Jiangsu Yanshen Biological ... shareholders for a total,cash consideration of approximately ...
Cached Biology Technology:CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 2CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 3CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 4Agendia Opens CLIA-Registered U.S. Genomics Laboratory 2Agendia Opens CLIA-Registered U.S. Genomics Laboratory 3Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. 2Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. 3
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Endocrine Society (ENDO) 95th Annual Meeting in San ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... ENDO 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... have used ancient shorelines to predict the stability of today,s ... high shoreline from three million years ago, for example ... thought to be evidence of a high sea level due ... led many scientists to think that if the world,s largest ... just the same in our modern, progressively warming world. ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... the rapid, mysterious death of phytoplankton in the North ... Rutgers University and the Woods Hole Oceanographic Institution (WHOI). ... cancer research. The team discovered a previously unknown ... been attacking and killing Emiliania huxleyi , a ...
... A nutritionist whose research was instrumental in adding fruits and ... subsidy will receive the March of Dimes Agnes Higgins Award ... Gail Harrison, Ph.D., MNS, , a professor in ... California, Los Angeles School of Public Health, will receive the ...
... of a gene through deletion of genetic material on chromosome ... said a consortium of researchers led by Baylor College of ... today in the journal Nature Genetics . "This ... these problems in a specific group of individuals to this ...
Cached Biology News:Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Developmental delay could stem from nicotinic receptor deletion 2
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
pETDuet-1 is designed for the coexpression of two target genes....
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Mouse Laminin-1 MAb (Clone AL-3)...
Biology Products: